153 related articles for article (PubMed ID: 37159056)
21. Chapter 17: Genital human papillomavirus infections--current and prospective therapies.
Stanley M
J Natl Cancer Inst Monogr; 2003; (31):117-24. PubMed ID: 12807955
[TBL] [Abstract][Full Text] [Related]
22. [The first vaccine against cancer: the human papillomavirus vaccine].
Bősze P
Orv Hetil; 2013 Apr; 154(16):603-18. PubMed ID: 23587540
[TBL] [Abstract][Full Text] [Related]
23. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia.
Palefsky JM; Giuliano AR; Goldstone S; Moreira ED; Aranda C; Jessen H; Hillman R; Ferris D; Coutlee F; Stoler MH; Marshall JB; Radley D; Vuocolo S; Haupt RM; Guris D; Garner EI
N Engl J Med; 2011 Oct; 365(17):1576-85. PubMed ID: 22029979
[TBL] [Abstract][Full Text] [Related]
24. Immune responses against virus and tumor in cervical carcinogenesis: treatment strategies for avoiding the HPV-induced immune escape.
Conesa-Zamora P
Gynecol Oncol; 2013 Nov; 131(2):480-8. PubMed ID: 23994536
[TBL] [Abstract][Full Text] [Related]
25. Spontaneous and Vaccine-Induced Clearance of Mus Musculus Papillomavirus 1 Infection.
Jiang RT; Wang JW; Peng S; Huang TC; Wang C; Cannella F; Chang YN; Viscidi RP; Best SRA; Hung CF; Roden RBS
J Virol; 2017 Aug; 91(15):. PubMed ID: 28515303
[TBL] [Abstract][Full Text] [Related]
26. Human papillomavirus vaccines and anal carcinoma.
Franceschi S; De Vuyst H
Curr Opin HIV AIDS; 2009 Jan; 4(1):57-63. PubMed ID: 19339940
[TBL] [Abstract][Full Text] [Related]
27. In silico/In vivo analysis of high-risk papillomavirus L1 and L2 conserved sequences for development of cross-subtype prophylactic vaccine.
Namvar A; Bolhassani A; Javadi G; Noormohammadi Z
Sci Rep; 2019 Oct; 9(1):15225. PubMed ID: 31645650
[TBL] [Abstract][Full Text] [Related]
28. Human papillomavirus vaccines and adolescents.
Kahn JA; Bernstein DI
Curr Opin Obstet Gynecol; 2005 Oct; 17(5):476-82. PubMed ID: 16141761
[TBL] [Abstract][Full Text] [Related]
29. Incidence and clinical management of oral human papillomavirus infection in men: a series of key short messages.
Videla S; Darwich L; Cañadas M; Clotet B; Sirera G
Expert Rev Anti Infect Ther; 2014 Aug; 12(8):947-57. PubMed ID: 24865412
[TBL] [Abstract][Full Text] [Related]
30. Prophylactic HPV vaccination: past, present, and future.
Castle PE; Maza M
Epidemiol Infect; 2016 Feb; 144(3):449-68. PubMed ID: 26429676
[TBL] [Abstract][Full Text] [Related]
31. Clinical trials of human papillomavirus vaccines and beyond.
Lehtinen M; Dillner J
Nat Rev Clin Oncol; 2013 Jul; 10(7):400-10. PubMed ID: 23736648
[TBL] [Abstract][Full Text] [Related]
32. Prevention strategies against human papillomavirus in males.
Garland SM
Gynecol Oncol; 2010 May; 117(2 Suppl):S20-5. PubMed ID: 20138347
[TBL] [Abstract][Full Text] [Related]
33. Human Papillomavirus and Genital Warts: A Review of the Evidence for the 2015 Centers for Disease Control and Prevention Sexually Transmitted Diseases Treatment Guidelines.
Park IU; Introcaso C; Dunne EF
Clin Infect Dis; 2015 Dec; 61 Suppl 8():S849-55. PubMed ID: 26602622
[TBL] [Abstract][Full Text] [Related]
34. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
Markowitz LE; Dunne EF; Saraiya M; Lawson HW; Chesson H; Unger ER; ;
MMWR Recomm Rep; 2007 Mar; 56(RR-2):1-24. PubMed ID: 17380109
[TBL] [Abstract][Full Text] [Related]
35. Natural and vaccine-induced B cell-derived systemic and mucosal humoral immunity to human papillomavirus.
Mboumba Bouassa RS; Péré H; Jenabian MA; Veyer D; Meye JF; Touzé A; Bélec L
Expert Rev Anti Infect Ther; 2020 Jun; 18(6):579-607. PubMed ID: 32242472
[No Abstract] [Full Text] [Related]
36. Immune responses to human papilloma viruses.
Stanley MA
Indian J Med Res; 2009 Sep; 130(3):266-76. PubMed ID: 19901436
[TBL] [Abstract][Full Text] [Related]
37. HPV vaccination and the effects on rates of HPV-related cancers.
St Laurent J; Luckett R; Feldman S
Curr Probl Cancer; 2018 Sep; 42(5):493-506. PubMed ID: 30041818
[TBL] [Abstract][Full Text] [Related]
38. Human papillomavirus type-distribution in vulvar and vaginal cancers and their associated precursors.
Smith JS; Backes DM; Hoots BE; Kurman RJ; Pimenta JM
Obstet Gynecol; 2009 Apr; 113(4):917-924. PubMed ID: 19305339
[TBL] [Abstract][Full Text] [Related]
39. Epitope specificity and longevity of a vaccine-induced human T cell response against HPV18.
Smith KL; Tristram A; Gallagher KM; Fiander AN; Man S
Int Immunol; 2005 Feb; 17(2):167-76. PubMed ID: 15623547
[TBL] [Abstract][Full Text] [Related]
40. A novel recombinant protein vaccine containing the different E7 proteins of the HPV16, 18, 6, 11 E7 linked to the HIV-1 Tat (47-57) improve cytotoxic immune responses.
Mousavi T; Valadan R; Rafiei A; Abbasi A; Haghshenas MR
Biotechnol Lett; 2021 Sep; 43(9):1933-1944. PubMed ID: 34313864
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
